研究单位：[1]Vice-Director Liver Research Centre,Beijing Friendship Hospital[2]Tongji Hospital,Tongji Medical College,Huazhong University of Science ＆Technology Wuhan,Hubei,China,300030[3]Sir Run Run Shaw Hospital,School of Medicine,Zhejiang University Hangzhou,Jiangsu,China,310016[4]The Affiliated Hospital of Yanbian University Yanbian,Jilin,China,133000[5]RenjiHospital,Shanghai Jiao Tong University,School of Medicine Shanghai,Shanghai,China,200032[6]Beijing Ditan Hospital,Capital Medical University Beijing,Beijing,China,100015
研究目的：
Six hundreds patients with chronic hepatitis B clinically diagnosed as compensated liver cirrhosis are randomly assigned in a 1:1 ratio. One arm is entecavir alone for 2 years; the other is entecavir alone for the first 0.5 year, entecavir plus thymosin-α for 1 year, entecavir for another additional 0.5 year.Patients will be assessed at baseline, at every six months for blood cell count, liver function test, HBVDNA, AFP, prothrombin time, liver ultrasonography, and Fibroscan;
